NovioSense Announces Positive Phase 2 Clinical Trial Results and the Commencement of a Second Follow Up Study
NovioSense BV, the venture capital-backed clinical stage medical device company, today announced positive data from its NLNSGS2017-02 Phase 2 tear glucose sensor study. The NovioSense Glucose Sensor is a device that, when placed in the lower eyelid, continuously measures glucose levels in the tear fluid of diabetic patients. The results of the six-patient clinical trial are presented in the American Chemical Society Journal Biomacromolecules.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181025005032/en/
NovioSense non-invasive tear glucose sensor (Photo: Business Wire)
Dr. Wilson, NovioSense’s CEO, said, “Today marks an important step in our tear glucose program. We opted to deploy the tear glucose sensor in diabetic patients to obtain evidence that tear glucose levels may be utilised to predict blood glucose levels with a clinically acceptable accuracy. These positive results from our phase 2 study demonstrate that the NovioSense Glucose Sensor can be used to measure glucose non-invasively in tears and correlates to blood glucose levels with an accuracy comparable to commercial, minimally invasive devices.”
The completed Phase 2 study in six diabetic patients was initiated based on positive results from a Phase 1 pilot safety study in 6 healthy subjects. On October 18, 2018 NovioSense initiated a follow-on study, NLNSGS2018-02, in 24 diabetic patients to gather additional evidence for the use of its sensor platform for diabetic patients.
Linze Dijkstra, Managing Partner of Health Innovations, said, “We invested in NovioSense in 2012 based on positive pre-clinical data and are delighted to see year-on-year progress in the development of this disruptive diagnostic platform.”
NovioSense BV has developed a flexible miniature sensor that, when placed in the lower eyelid, provides glucose measurements directly to a smartphone. NovioSense delivers the first of its kind eye-wearable, wireless, battery-free glucose sensor to provide pain-free, continuous glucose monitoring to all individuals with diabetes at an affordable price. The non-invasive sensor platform, which utilises NFC technology, is placed by the patient to continuously monitor glucose readings, as a useful component of any glucose management system.
Website: www.noviosense.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181025005032/en/
Contact information
NovioSense BV
Christopher Wilson
c.wilson@noviosense.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KuppingerCole Recognizes Regula as One of the Innovation Leaders in Identity Verification10.6.2025 04:00:00 EEST | Press release
Regula, a global developer of forensic devices and identity verification (IDV) solutions, has made its inaugural appearance in the KuppingerCole Leadership Compass for Identity Verification 2025. Mentioned in the Innovation Leaders category, the company is recognized for its 100% in-house R&D, forensic-grade technology, global document coverage, and advanced liveness detection capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609760424/en/ Regula’s innovative in-house technology powers fast, seamless identity checks—now recognized by KuppingerCole Analysts. Specializing in IDV and cybersecurity industry analysis, KuppingerCole forecasts that the global IDV market will grow from $18.4 billion in 2025 to $50.07 billion by 2030, driven by increasing identity fraud, compliance requirements, user expectations, and technological advancements. As identity verification rapidly shifts toward fully remote and automated e
IFF Appoints Virginia “Gina” Drosos to Board of Directors10.6.2025 00:46:00 EEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. “We are very pleased to welcome Gina to the IFF board,” said Kevin O’Byrne, chair of the board. “Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders.” Drosos most recently served as chief executive officer and a director of Signet Jewelers Ltd. (NYSE: SIG)—the world’s largest retailer of diamond jewelry—from August 2017 to November 2024. During her tenure, she led the company through a significant transformation, expanding its digital capabilities and enhancing customer experien
Vantage Data Centers Completes Industry’s First Euro-Based Data Center Asset-Backed Securitization (ABS) with €640M Transaction9.6.2025 19:00:00 EEST | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised €640 million in securitized term notes, marking the first-ever euro-based securitization of data center assets in Continental Europe. The transaction includes an additional €80 million in unfunded Variable Funding Notes. The Class A-2 Notes are rated A-, and the Class B Notes are rated BBB- by Standard & Poor’s and Scope Ratings. This transaction follows Vantage’s success last year with the first-ever EMEA data center ABS completed in British pound sterling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609592365/en/ Pictured is BER11, part of Vantage’s first Berlin campus located in Brandenburg Park. The notes will be used to refinance four data centers in Germany, two in Offenbach, Frankfurt, and two in Berlin, all of which are fully leased to hyperscale customers. The refinancing is part of Vantage’s wider
Uniphore Launches Business AI Cloud: A Sovereign, Composable & Secure AI Platform to Power the Agentic Enterprise9.6.2025 16:04:00 EEST | Press release
Uniphore, the Business AI company, today launched the Uniphore Business AI Cloud: a sovereign, composable, and secure platform that bridges the “AI divide” between IT and business users by combining the simplicity of consumer AI with enterprise-grade security and scalability. While AI technologies rapidly reshape the enterprise, there has been little focus on deploying AI in a way that empowers CIOs to scale it securely across the organization while enabling business users to intuitively access AI with the full power of enterprise data, integrations, and context. IT and business must be united through a single AI platform to fulfill AI’s promise as a transformative force for business. Introducing the Business AI Cloud Uniphore’s Business AI Cloud powers the agentic enterprise with a full-stack AI platform spanning data, knowledge, models, and agents. It empowers business users to deploy AI agents and tap into enterprise knowledge instantly, while giving CIOs the foundation to deliver s
Capcom’s Resident Evil Requiem , the Latest Title in the Series, Set to Release on February 27, 2026!9.6.2025 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series, is scheduled for release on February 27, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609946595/en/ Resident Evil Requiem Logo Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development expertise cultivated through numerous hit titles. The graphical fidelity has undergone a significant evolution in particular, delivering visuals with cinematic realism that vividly convey characters’ emotions and offer an unprecedented level of immersion. The company is developing the title steadily to meet the high expectations of both long-time series’ fans and the global gaming audience. Further details regarding the title will be announced in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom